Wigen was established in 2018 by a team of enthusiastic researchers and business innovators who held a shared vision for creating small molecule medications to combat cancer, one of the most challenging diseases in human history. Wigen concentrates on areas with significant unmet medical requirements and is committed to producing small molecule drugs that influence emerging therapeutic targets. We also investigate cutting-edge technologies that facilitate drug discovery in general. At Wigen, we prioritize integrity, creativity, and inclusivity. Our goal is to establish a nurturing and supportive environment that fosters both individual and company growth. We are dedicated to fostering a culture of success.